[The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
The authors' findings say about compatibility of clinical responses to naftidrofuril (daily dose 600 mg) and pentoxifillin (daily dose 600 mg) in patients with atherosclerosis of the lower limb artery and intermittent claudication stage II. Both the drugs had minimal effects on coagulant and fibrinolytic systems and platelet aggregation.
Komarov
A L
AL
Panchenko
E P
EP
Eshkeeva
A R
AR
Dobrovol'skiĭ
A B
AB
Titaeva
E V
EV
Karpov
Iu A
IuA
D004341:Drug Evaluation; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007383:Intermittent Claudication / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use*; D010431:Pentoxifylline / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D012702:Serotonin Antagonists; D014665:Vasodilator Agents; D009257:Nafronyl; D010431:Pentoxifylline
Antagonist serotoninovykh retseptorov II tipa naftidrofuril pri lechenii bol'nykh s peremezhaiushcheĭsia khromotoĭ.